The Experts below are selected from a list of 271059 Experts worldwide ranked by ideXlab platform
John H. Edmonson - One of the best experts on this subject based on the ideXlab platform.
-
Progress in the Systemic Treatment of advanced soft-tissue sarcomas
Cancer Control, 1998Co-Authors: Scott H. Okuno, John H. EdmonsonAbstract:Background: Despite the plethora of chemotherapeutic remedies for advanced soft-tissue sarcomas, little evidence has developed to indicate that these efforts have been curative. No controlled comparison has yet proven that patients receiving multidrug regimens survive longer than those receiving doxorubicin alone. Methods: The authors review current Systemic Treatments and then discuss some investigational efforts now in progress. Also, they seek to demonstrate how the therapies currently available can be integrated with surgery and radiation therapy to accomplish more than might be anticipated from chemotherapy alone. Results: While working to develop better Systemic therapies for advanced soft-tissue sarcomas, the integrated use of our best chemotherapy regimens in combination with selected surgical and radiotherapy efforts may provide patients with the best available therapy. Some recent observations involving the use of molgramostim plus chemotherapy have been intriguing. Conclusions: Progress in the Systemic Treatment of advanced soft-tissue sarcomas may be gradual, but it is real. Our daily challenge is to be certain that we offer each patient the best available multimodality Treatment applicable to his or her clinical situation. Molgramostim should be made available for further study with chemotherapy in controlled clinical trials.
Gabe S. Sonke - One of the best experts on this subject based on the ideXlab platform.
-
Doctors' reports about palliative Systemic Treatment: A medical record study.
Palliative medicine, 2016Co-Authors: Hilde M. Buiting, Mirian Brink, Marleen N Wijnhoven, Martine E Lokker, Lydia Gm Van Der Geest, Wim E Terpstra, Gabe S. SonkeAbstract:Background:Decisions about palliative Systemic Treatment are key elements of palliative and end-of-life care. Such decisions must often be made in complex, clinical situations.Aim:To explore the content of medical records of patients with advanced non-small cell lung cancer and pancreatic cancer with specific emphasis on doctors’ notes about decisions on palliative Systemic Treatment.Design:Medical record review (2009–2012) of 147 cancer patients containing 276 notes about palliative Systemic Treatment. We described the proportion of notes/medical records containing pre-specified items relevant to palliative Systemic Treatment. We selected patients using the nationwide Netherlands Cancer Registry.Setting:Hospital based.Results:About 75% of all notes reported doctors’ considerations to start/continue palliative Systemic Treatment, including information about the prognosis (47%), possible survival gain (22%), patients’ wish for palliative Systemic Treatment (33%), impact on quality of life (8%), and patient...
-
marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant Systemic Treatment in breast cancer patients the mari procedure
Annals of Surgery, 2015Co-Authors: M Donker, Gabe S. Sonke, Marieke E Straver, Jelle Wesseling, Claudette E Loo, Margaret Schot, C A Drukker, Harm Van Tinteren, Emiel Th J Rutgers, Mariejeanne Vrancken T F D PeetersAbstract:Objective:The MARI procedure [marking the axillary lymph node with radioactive iodine (125I) seeds] is a new minimal invasive method to assess the pathological response of nodal metastases after neoadjuvant Systemic Treatment (NST) in patients with breast cancer. This method allows axilla-conserving
Scott H. Okuno - One of the best experts on this subject based on the ideXlab platform.
-
Progress in the Systemic Treatment of advanced soft-tissue sarcomas
Cancer Control, 1998Co-Authors: Scott H. Okuno, John H. EdmonsonAbstract:Background: Despite the plethora of chemotherapeutic remedies for advanced soft-tissue sarcomas, little evidence has developed to indicate that these efforts have been curative. No controlled comparison has yet proven that patients receiving multidrug regimens survive longer than those receiving doxorubicin alone. Methods: The authors review current Systemic Treatments and then discuss some investigational efforts now in progress. Also, they seek to demonstrate how the therapies currently available can be integrated with surgery and radiation therapy to accomplish more than might be anticipated from chemotherapy alone. Results: While working to develop better Systemic therapies for advanced soft-tissue sarcomas, the integrated use of our best chemotherapy regimens in combination with selected surgical and radiotherapy efforts may provide patients with the best available therapy. Some recent observations involving the use of molgramostim plus chemotherapy have been intriguing. Conclusions: Progress in the Systemic Treatment of advanced soft-tissue sarcomas may be gradual, but it is real. Our daily challenge is to be certain that we offer each patient the best available multimodality Treatment applicable to his or her clinical situation. Molgramostim should be made available for further study with chemotherapy in controlled clinical trials.
Winette T. A. Graaf - One of the best experts on this subject based on the ideXlab platform.
-
Systemic Treatment for Adults with Synovial Sarcoma
Current Treatment Options in Oncology, 2018Co-Authors: Ingrid M. E. Desar, Emmy D. G. Fleuren, Winette T. A. GraafAbstract:Synovial sarcoma (SS) is a rare, yet highly malignant, type of soft tissue sarcoma (STS), for which survival has not improved significantly during the past years. In this review, we focus on Systemic Treatment in adults. Compared to other STS, SS are relatively chemosensitive. Ifosfamide and ifosfamide combinations are active in different lines of Treatment. In high-risk extremity and chest wall STS, neoadjuvant doxorubicin and ifosfamide has shown as much activity as high-dose ifosfamide. There are indications that combination chemotherapy with doxorubicin and ifosfamide in this setting improves outcome. In the first-line metastatic setting, combination Treatment with doxorubicin and ifosfamide is a preferred option in fit patients, while in other patients, sequential doxorubicin and ifosfamide can be considered. In second and later lines, pazopanib and trabectedin have shown activity. Many new approaches to treat metastatic SS are currently under investigation, both preclinical as well as clinical, including other receptor tyrosine kinase inhibitors, epigenetic modulators, compounds interfering with DNA damage response (DDR), and immunotherapy.
Á. León - One of the best experts on this subject based on the ideXlab platform.
-
Systemic Treatment of Moderate to Severe Psoriasis in Pediatric Patients in Galicia, Spain: A Descriptive Study.
Actas dermo-sifiliograficas, 2018Co-Authors: A. Batalla, Rosa Fernández-torres, L. Rodríguez-pazos, Benigno Monteagudo, R. Pardavila-riveiro, Romina Rodríguez-lojo, A. Zulaica, Miguel Cabanillas, Eduardo Fonseca, Á. LeónAbstract:Abstract Background and objective Studies on the use of Systemic therapy for psoriasis in pediatric patients are scarce. The main aim of this study was to describe the Systemic Treatments used for moderate to severe psoriasis in pediatric clinical settings. The second aim was to describe the effectiveness and safety of these Treatments. Material and methods Descriptive, cross-sectional, multicenter study of patients under 18 years of age with moderate to severe psoriasis who were being treated or had been treated with a Systemic drug (conventional or biologic) or phototherapy. We recorded demographic and clinical information, Treatments received, tolerance, adverse effects, and response to Treatment. Results Data were collected for 40 patients (60% female; mean age, 13 years) who had received 63 Treatments in total. The most common first Treatment (n = 40) was phototherapy (administered to 68% of patients), followed by acitretin (15%). The most common Treatments overall (n = 63) were phototherapy (57%) and methotrexate (16%). At week 12 (evaluation of Systemic Treatment and phototherapy), 66% of the patients were classified as good responders and 22% as partial responders. The respective rates for week 24 (evaluation of Systemic Treatment only) were 36% and 32%. The Treatments were well tolerated (97%) and adverse effects were reported in just 11% of cases. There were no Treatment discontinuations because of adverse effects. Conclusions Phototherapy, followed by methotrexate, were the most common Treatment for moderate to severe psoriasis in this series of patients under 18 years. The Treatments showed a favorable safety profile and were associated with a good response rate of 66% at week 12 (Systemic Treatment and phototherapy) and 36% at week 24 (Systemic Treatment only).
